Literature DB >> 2193075

Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial.

M Campieri1, P Gionchetti, A Belluzzi, C Brignola, M Tampieri, P Iannone, G Brunetti, M Miglioli, L Barbara.   

Abstract

Sixty-two patients with ulcerative colitis localised to the distal sigmoid colon and rectum (less than 20 cm) entered the trial. Thirty-two were treated with 5-ASA 500 mg suppositories (Asacol) 3 times a day for 1 month while 30 received a placebo given in the same regime. Clinical, sigmoidoscopic and histological assessment was carried out before, after 15 days and after 1 month of treatment. At the end of the study 5-ASA suppositories showed significantly better results in all the parameters recorded than placebo (p less than 0.01). There were no unwanted effects related to the use of suppositories. This treatment should therefore be offered as a first choice for patients with distal rectosigmoiditis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193075     DOI: 10.1007/bf00298473

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  9 in total

1.  Biopsy studies in ulcerative colitis.

Authors:  S C TRUELOVE; W C RICHARDS
Journal:  Br Med J       Date:  1956-06-09

2.  5-Aminosalicylic acid suppositories in the management of ulcerative colitis.

Authors:  M Campieri; P Gionchetti; A Belluzzi; C Brignola; F Torresan; M Tampieri; P Iannone; M Miglioli; L Barbara
Journal:  Dis Colon Rectum       Date:  1989-05       Impact factor: 4.585

3.  Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis.

Authors:  M Campieri; G A Lanfranchi; C Brignola; G Bazzocchi; P Gionchetti; M R Minguzzi; I P Cappello; C Corbelli; S Boschi
Journal:  Dis Colon Rectum       Date:  1986-02       Impact factor: 4.585

4.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

5.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.

Authors:  C N Williams; G Haber; J A Aquino
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 6.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

Authors:  O H Nielsen; K Bukhave; J Elmgreen; I Ahnfelt-Rønne
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

8.  5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?

Authors:  M Campieri; P Gionchetti; A Belluzzi; C Brignola; G M Tabanelli; M Miglioli; L Barbara
Journal:  J Clin Gastroenterol       Date:  1988-08       Impact factor: 3.062

9.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

Authors:  L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

  9 in total
  8 in total

1.  Meta-analysis of the placebo response in ulcerative colitis.

Authors:  Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily B Levitan; Ciaran P Kelly
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

2.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Fernando Gomollón; José Maté; José María Pajares
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

3.  Ulcerative proctitis.

Authors:  Charles B Whitlow
Journal:  Clin Colon Rectal Surg       Date:  2004-02

4.  A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis.

Authors:  Mark Lamet
Journal:  Dig Dis Sci       Date:  2010-07-30       Impact factor: 3.199

5.  Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis.

Authors:  Xiaojing Zhao; Changcheng Zhou; Jingjing Ma; Yunjuan Zhu; Min Sun; Peixue Wang; Yi Zhang; Haiqin Ma; Hongjie Zhang
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

6.  Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.

Authors:  Melvin B Heyman; Jaroslaw Kierkus; Jean Spénard; Hadia Shbaklo; Monique Giguere
Journal:  Inflamm Bowel Dis       Date:  2010-11       Impact factor: 5.325

Review 7.  Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

Authors:  Vipul Jairath; G Y Zou; Claire E Parker; John K MacDonald; Turki AlAmeel; Mohammad Al Beshir; Majid A Almadi; Talal Al-Taweel; Nathan Ss Atkinson; Sujata Biswas; Thomas Chapman; Parambir S Dulai; Mark A Glaire; Daniël R Hoekman; Andreas Koutsoumpas; Elizabeth Minas; Mahmoud H Mosli; Mark Samaan; Reena Khanna; Simon Travis; Geert D'Haens; William J Sandborn; Brian G Feagan
Journal:  Cochrane Database Syst Rev       Date:  2017-09-08

8.  Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease.

Authors:  Christopher J Kiely; Angela Clark; Joya Bhattacharyya; Gordon W Moran; James C Lee; Miles Parkes
Journal:  Dig Dis Sci       Date:  2018-02-19       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.